Dr. Afsaneh Barzi, MD

Dr. Barzi practices at City of Hope Helford Clinical Research Hospital in Duarte, California.

Dr. Barzi's NPI, 1265480412, was assigned on May 4, 2006. Dr. Barzi graduated from Tehran University of Medical Sciences School of Medicine in 1996. Dr. Barzi holds California license A117268.

Dr. Barzi's primary practice is City of Hope Helford Clinical Research Hospital, at 1500 E Duarte Road, Duarte, CA.

Dr. Barzi's primary practice is City of Hope Helford Clinical Research Hospital in Duarte, California. The medical group on file is USC Care Medical Group. Dmand AI also links Dr. Barzi to 1 more breast imaging center, 1 group practice or clinic and 1 medical group, each named with a free account. Dr. Barzi's employer is on file too.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Barzi practices, 3 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Barzi's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Barzi is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Dr. Barzi's licenses on file in 6 states: California, Nevada, Alaska, Rhode Island, Ohio and Texas.

Dmand AI lists chronic anemia and colorectal cancer among the conditions Dr. Barzi treats.

CMS data shows 131 Medicare services from Dr. Barzi across 2 procedure codes in 2024, all of them office visits, for 64 Medicare patients. Medicare paid $9,200 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 64 Medicare patients who saw Dr. Barzi in 2024. The largest group is 65 to 74, with 36 patients. 72% of them have high blood pressure, and 66% have high cholesterol. 31% are also on Medicaid. Their average risk score is 3.07, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Barzi's median patient age at 64, with 67% women.

In 2024, Dr. Barzi wrote 106 Medicare Part D claims for 31 patients. 85% of them were for generic drugs. CMS names the drug for 11 of them, across 1 drug with 11 or more claims each, at $70 in total drug cost. In 2023, CMS named 67 claims across 4 drugs.

Dmand AI links 32 papers to Dr. Barzi, published from 2013 to 2024. 2020 was the busiest year, with 7. Dr. Barzi's most frequent co-authors are Heinz-Josef Lenz, MD, Sarmad Sadeghi, MD, MS, PhD and Diana L. Hanna, MD.

Dmand AI links Dr. Barzi to 10 clinical trials, 4 of them phase 2 studies. 2 are still active or recruiting. Conditions studied include Rectal Diseases, Rectal Neoplasms and Colorectal Neoplasms. University of Southern California sponsors the most, 7.

CMS Open Payments shows 134 general payments to Dr. Barzi from 23 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 74% of the total. Bayer HealthCare Pharmaceuticals Inc. paid the most, $43,573.

Dmand AI lists 2 awards for Dr. Barzi, most recently Top Doctors:LA Area in 2013.

Dr. Barzi graduated from Tehran University of Medical Sciences School of Medicine in 1996. Dr. Barzi is a member of ACP and ASCO.

Dr. Barzi is in network with 5 carriers, including Elevance, Blue Cross Blue Shield of Michigan and Blue Cross Blue Shield of Massachusetts. Medicare plans come from the most carriers, 5. Check the plan with the practice before a visit.